From a public health question to a reference dose
The question started with a number. Through the 1980s, neural tube defect rates were reported at roughly 7 per 1,000 births in high-incidence regions, 3–6 per 1,000 in the United Kingdom, and about 1 per 1,000 worldwide. Researchers at the 1983 international perinatal meeting treated that gap as a nutrition problem worth testing, and folate became the candidate.
The work moved quickly into international collaboration. A research relationship with the US Centers for Disease Control and Prevention began in 1984 and was formalised in 1986, and an international research programme on neural tube defect prevention launched in 1991.
The programme ran for 13 years and covered 250,000 women of childbearing age, with more than US$20 million invested. Its results were published in The Lancet in 1997, and the 0.4 mg dose it established became the reference dose cited in WHO guidance and in pharmacopoeial standards from the United States, Britain, Europe and Japan.
- Stated population, stated need.
- Identity and origin per lot.
- Formats differ for a reason.
- Adherence is a design problem.
- Reviewed before the label.